

## Prof. ÖMER DİZDAR

### Personal Information

Office Phone: [+90 312 305 4330](tel:+903123054330)

Email: [omer.dizdar@hacettepe.edu.tr](mailto:omer.dizdar@hacettepe.edu.tr)

Web: <https://avesis.hacettepe.edu.tr/omer.dizdar>

Address: Hacettepe Üniversitesi Kanser Enstitüsü Prevanatif Onkoloji ABD, Altındağ, ANKARA

### Education Information

Postgraduate, Hacettepe Üniversitesi, Kanser Enstitüsü , Prevanatif Onkoloji Ad, Turkey 2015 - 2017

Post Doctorate of Medicine, Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Abd Medikal Onkoloji Bölümü, Turkey 2005 - 2009

Expertise In Medicine, Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Abd, Turkey 2000 - 2005

Undergraduate, Hacettepe Üniversitesi, Tıp Fakültesi (İng), Turkey 1994 - 2000

### Foreign Languages

English, C1 Advanced

### Dissertations

Postgraduate, Kronik periodontiti olan hastalarda kanser insidansının değerlendirilmesi, Hacettepe Üniversitesi, Kanser Enstitüsü , Prevanatif Onkoloji Ad, 2017

Expertise In Medicine, Aromataz inhibitörü kullanan meme kanserli hastalarda artralji sıklığı ve patogenezinin araştırılması, Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Ad Tıbbi Onkoloji Bölümü, 2009

Expertise In Medicine, Multiple myelomalı hastalarda kemik tutulumunun belirlenmesinde kemik rezorbsiyon belirteçlerinin rolü, Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Ad, 2005

### Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Oncology

### Academic Titles / Tasks

Professor, Hacettepe Üniversitesi, Kanser Enstitüsü , Prevanatif Onkoloji Ad, 2017 - Continues

### Academic and Administrative Experience

Hacettepe Üniversitesi, 2016 - Continues

### Advising Theses

DİZDAR Ö., Kanser tanısı alan hastaların birinci dereceden yakınlarında sigara bırakma davranışının değerlendirilmesi, Postgraduate, B.HÜSEYİN(Student), 2018  
DİZDAR Ö., Kolon kanseri ve tükürük mikrobiyom ilişkisi, Expertise In Medicine, D.CAN(Student), 2018  
DİZDAR Ö., Kolorektal kanser tanısı alan premenopozal kadınlarda adjuvan kemoterapiye bağlı amenore sıklığı ve ilişkili faktörlerin belirlenmesi, Expertise In Medicine, T.ŞAHİN(Student), 2017

## Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

- I. **Adjuvant treatment with paclitaxel plus trastuzumab for node-negative breast cancer: real-life experience**  
Diker O., AKTAŞ B. Y. , Ak R., KÖYLÜ B., BAŞ O., TABAN H., GÜVEN D. C. , Olgun P., KERTMEN N., DİZDAR Ö., et al.  
FUTURE ONCOLOGY, 2021 (Journal Indexed in SCI)
- II. **HER2-low breast cancer could be associated with an increased risk of brain metastasis**  
GÜVEN D. C. , KAYA M. B. , Fedai B., ÖZDEN M., YILDIRIM H. Ç. , KÖSEMEHMETOĞLU K., KERTMEN N., DİZDAR Ö., ÜNER A., AKSOY S.  
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021 (Journal Indexed in SCI)
- III. **Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better? Comment**  
Güven D. C. , Taban H., Dizdar O.  
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021 (Journal Indexed in SCI)
- IV. **Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality**  
GÜVEN D. C. , ŞAHİN T. K. , YILDIRIM H. Ç. , ÇEŞMECİ E., Incesu F. G. G. , TAHILLIOĞLU Y., ÜÇGÜL E., AKSUN M. S. , GÜRBÜZ S. Ç. , AKTEPE O. H. , et al.  
BMJ SUPPORTIVE & PALLIATIVE CARE, 2021 (Journal Indexed in SCI)
- V. **Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards**  
GÜVEN D. C. , EROĞLU İ., İsmayilov R., ULUSOYDAN E., AKTEPE O. H. , TELLİ DİZMAN G., ARIK Z., DİZDAR Ö., ÜNAL S., METAN G., et al.  
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021 (Journal Indexed in SCI)
- VI. **Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors**  
GÜVEN D. C. , AKTEPE O. H. , TABAN H., AKTAŞ B. Y. , GÜNER G., YILDIRIM H. H. , ŞAHİN T. K. , AKSUN M. S. , DİZDAR Ö., AKSOY S., et al.  
BIOMARKERS IN MEDICINE, vol.15, no.13, pp.1123-1130, 2021 (Journal Indexed in SCI)
- VII. **Sarcopenia and anthracycline cardiotoxicity in patients with cancer**  
BAŞ O., ERDEMİR A. G. , ONUR M. R. , ÖZER N., ŞENER Y. Z. , AKSU S., BARIŞTA İ., GÜNER G., GÜVEN D. C. , KERTMEN N., et al.  
BMJ SUPPORTIVE & PALLIATIVE CARE, 2021 (Journal Indexed in SCI)
- VIII. **THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY**  
GÜVEN D. C. , ÖZBEK D. A. , ŞAHİN T. K. , AKSUN M. S. , KAVGACI G., Cebayilov C., YILDIRIM T., DİZDAR Ö., AKSOY S., KILIÇKAP S., et al.  
NEPHROLOGY DIALYSIS TRANSPLANTATION, vol.36, 2021 (Journal Indexed in SCI)
- IX. **Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy**  
GÜVEN D. C. , AKSUN M. S. , ŞAHİN T. K. , AKTEPE O. H. , YILDIRIM H. Ç. , TABAN H., Ceylan F., KERTMEN N., ARIK Z., DİZDAR Ö., et al.  
SUPPORTIVE CARE IN CANCER, 2021 (Journal Indexed in SCI)
- X. **PILE: a candidate prognostic score in cancer patients treated with immunotherapy**  
Güven D. C. , Yildirim H. C. , Bilgin E., Aktepe O. H. , Taban H., Sahin T. K. , Cakir I. Y. , Akin S., Dizdar O., Aksoy S., et al.

CLINICAL & TRANSLATIONAL ONCOLOGY, 2021 (Journal Indexed in SCI)

- XI. **Prognostic and predictive value of tumor-infiltrating lymphocytes in combination with systemic inflammatory markers in colon cancer**  
Efil S. C. , Guner G., Guven D. C. , Celikten B., Celebiyev E., Taban H., Akyol A., Kilickap S., YALÇIN S. S. , Dizdar O.  
ANNALS OF ONCOLOGY, vol.32, 2021 (Journal Indexed in SCI)
- XII. **The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy**  
AKTEPE O. H. , GÜVEN D. C. , ŞAHİN T. K. , YILDIRIM H. Ç. , ÇELİKTEN B., Yeter H. H. , YÜCE D., DİZDAR Ö., ERMAN M.  
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2021 (Journal Indexed in SCI)
- XIII. **What to expect from NCCN BRCA testing criteria: A retrospective cohort analysis**  
Aktas B. Y. , Degirmenciler R. F. , Durmaz C. D. , Taban H., Guven D. C. , Guner G., Yildirim H. C. , Demir M., Kertmen N., Arik Z., et al.  
ANNALS OF ONCOLOGY, vol.32, 2021 (Journal Indexed in SCI)
- XIV. **Clinical features and outcomes of COVID-19 in patients with solid tumors: Turkish National Registry Data**  
Ozdemir N., DİZDAR Ö., YAZICI O., AKSOY S., Dede D. S. , Budakoglu B., METAN G., ALP A., BUDAKOĞLU I. İ. , Oksuzoglu O. B. C. , et al.  
INTERNATIONAL JOURNAL OF CANCER, 2020 (Journal Indexed in SCI)
- XV. **Predictive biomarkers for immunotherapy efficacy in non-small-cell lung cancer: current status and future perspectives**  
C Guven D., ŞAHİN T. K. , DİZDAR Ö., KILIÇKAP S.  
BIOMARKERS IN MEDICINE, vol.14, pp.1383-1392, 2020 (Journal Indexed in SCI)
- XVI. **Chemoimmunotherapy for the salvage treatment of Ewing sarcoma: A case report**  
GÜVEN D. C. , KILIÇKAP S., YILDIRIM H. Ç. , Ceylan F., BAŞ O., DİZDAR Ö.  
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2020 (Journal Indexed in SCI)
- XVII. **Comments on "Survival impact of adjuvant chemotherapy in patients with stageIIA colon cancer: Analysis of the National Cancer Database"**  
DİZDAR Ö.  
INTERNATIONAL JOURNAL OF CANCER, 2020 (Journal Indexed in SCI)
- XVIII. **All Positives May Not Be the Same in Pancreatic Cancer Lessons Learned From the Past**  
Ceylan F., GÜVEN D. C. , ŞAHİN T. K. , ÖZBEK D. A. , DİZDAR Ö.  
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.43, no.9, pp.676, 2020 (Journal Indexed in SCI)
- XIX. **Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors**  
GÜVEN D. C. , ŞAHİN T. K. , AKSUN M. S. , TABAN H., AKTEPE O. H. , METİN AKSU N., AKKAŞ M., ERMAN M., KILIÇKAP S., DİZDAR Ö., et al.  
SUPPORTIVE CARE IN CANCER, 2020 (Journal Indexed in SCI)
- XX. **Cancer incidence in Behcet's Disease.**  
Guven D. C. , Bolek E. C. , Altintop S. E. , Celikten B., Aktas B. Y. , Kiraz S., Gullu I. H. , Karadag O., Dizdar O.  
JOURNAL OF CLINICAL ONCOLOGY, vol.38, no.15, 2020 (Journal Indexed in SCI)
- XXI. **Cancer incidence in Behcet's disease**  
GÜVEN D. C. , BÖLEK E. Ç. , ALTINTOP S. E. , ÇELİKTEN B., AKTAŞ B. Y. , KİRAZ S., Gullu I., KARADAĞ Ö., DİZDAR Ö.  
IRISH JOURNAL OF MEDICAL SCIENCE, 2020 (Journal Indexed in SCI)
- XXII. **Complete responses to two different anti-PD1 agents in a metastatic melanoma patient**  
KILIÇKAP S., GÜVEN D. C. , AKTEPE O. H. , AKTAŞ B. Y. , DİZDAR Ö.  
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.2, pp.496-499, 2020 (Journal Indexed in SCI)
- XXIII. **Development of de novo psoriasis during nivolumab therapy in a patient with small cell lung cancer**  
GÜVEN D. C. , KILIÇKAP S., GÜNER G., TABAN H., DİZDAR Ö.  
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.1, pp.256-258, 2020 (Journal Indexed in SCI)
- XXIV. **The Effects of Different Treatment Modalities on the Disease Course and Survival in Patients with Hepatocellular Cancer**

- Lacin S., Karakas Y., DİZDAR Ö., KILIÇKAP S., Hassan M. M. , Xiao L., Kaseb A. O. , YALÇIN Ş.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.30, no.2, pp.94-102, 2020 (Journal Indexed in SCI)
- XXV. **Classifying sarcopenia: using median value or cut-off values?**  
BAŞ O., DİZDAR Ö.  
BREAST CANCER RESEARCH AND TREATMENT, vol.176, no.2, pp.479, 2019 (Journal Indexed in SCI)
- XXVI. **Exploiting DNA repair defects in breast cancer: from chemotherapy to immunotherapy**  
AKTAŞ B. Y. , Guner G., Guven D. C. , Arslan C., DİZDAR Ö.  
EXPERT REVIEW OF ANTICANCER THERAPY, vol.19, no.7, pp.589-601, 2019 (Journal Indexed in SCI)
- XXVII. **Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability**  
KILIÇKAP S., Onder S., DİZDAR Ö., ERMAN M., ÜNER A.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.83, no.6, pp.1195-1196, 2019 (Journal Indexed in SCI)
- XXVIII. **Cancer incidence in familial Mediterranean fever patients: a retrospective analysis from central Anatolia**  
BİLGİN E., DİZDAR Ö., Guven D. C. , Ceylan S., AYBI Ö., FIRLATAN B., KARDAŞ R. C. , YILDIRIM T., Hayran M. K. , KALYONCU U., et al.  
Rheumatology International, vol.39, no.6, pp.1045-1051, 2019 (Journal Indexed in SCI Expanded)
- XXIX. **Analysis of Fusobacterium nucleatum and Streptococcus gallolyticus in saliva of colorectal cancer patients**  
Güven D. C. , DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N. , KARAKOÇ D., HAMALOĞLU E., Lacin S., Karakas Y., KILIÇKAP S., Hayran M., et al.  
BIOMARKERS IN MEDICINE, vol.13, no.9, pp.725-735, 2019 (Journal Indexed in SCI)
- XXX. **The frequency and predictors of persistent amenorrhea in premenopausal women with colorectal cancer who received adjuvant chemotherapy**  
ŞAHİN T., DİZDAR Ö., Ozdemir N., Zengin N., Ates O., Oksuzoglu B., ŞENDUR M. A. N. , Bilgin B., DEMİR M., BOZBULUT U. B. , et al.  
ANTI-CANCER DRUGS, vol.30, no.3, pp.289-294, 2019 (Journal Indexed in SCI)
- XXXI. **Noninferiority for Short-HER or short-chemotherapy?**  
Aktas B. Y. , Guven D. C. , Dizdar O.  
ANNALS OF ONCOLOGY, vol.30, no.1, pp.147, 2019 (Journal Indexed in SCI)
- XXXII. **Evaluation of cancer risk in patients with periodontal diseases**  
Güven D. C. , DİZDAR Ö., AKMAN A. C. , Berker E., Yekeduz E., Ceylan F., Baspinar B., Akbiyik I., AKTAŞ B. Y. , YÜCE D., et al.  
TURKISH JOURNAL OF MEDICAL SCIENCES, vol.49, no.3, pp.826-831, 2019 (Journal Indexed in SCI)
- XXXIII. **When side effect becomes the effect: Efficacy of capecitabine in refractory psoriasis**  
Karakas Y., Vural S., DIKER O., DİZDAR Ö.  
DERMATOLOGIC THERAPY, vol.31, no.6, 2018 (Journal Indexed in SCI)
- XXXIV. **Glucocorticoids in breast cancer treatment: real benefit or selection bias?**  
Güner G., DİZDAR Ö.  
BREAST CANCER RESEARCH AND TREATMENT, vol.172, no.1, pp.243, 2018 (Journal Indexed in SCI)
- XXXV. **TRANSCULTURAL ADAPTATION OF EORTC-QLQ-CR29 SCALE INTO TURKISH, AND ASSESSMENT OF VALIDITY AND RELIABILITY IN TURKISH PATIENTS WITH COLORECTAL CANCER**  
HAYRAN K. M. , Yuce D., Kilickap S., Huseyin B., Erman M., Dizdar O., Celik I.  
VALUE IN HEALTH, vol.21, 2018 (Journal Indexed in SCI)
- XXXVI. **EFFECTS OF CANCER TYPES ON LOCAL AND OUT-OF-CITY ADMISSIONS FOR MEDICAL CARE**  
HAYRAN K. M. , Yuce D., Kilickap S., Dizdar O., Huseyin B., Erman M., Celik I.  
VALUE IN HEALTH, vol.21, 2018 (Journal Indexed in SCI)
- XXXVII. **The Effect of Total Size of Lesions in Multifocal/Multicentric Breast Cancer on Survival**  
KARAKAS Y., DİZDAR Ö., AKSOY S., Hayran M., Altundag K.  
CLINICAL BREAST CANCER, vol.18, no.4, pp.320-327, 2018 (Journal Indexed in SCI)
- XXXVIII. **Familial Mediterranean fever: new insights into cancer immunoprevention? Comment on the article**

by Brenner et al

BİLGİN E., Erden A., DİZDAR Ö.

ARTHRITIS & RHEUMATOLOGY, vol.70, no.7, pp.1167, 2018 (Journal Indexed in SCI)

- XXXIX. **Real world survival data of a rare malignancy: Anal cancer results in HIV negative patients from Turkey**  
ESİN E., YILDIZ F., Lacin S., KARAKAS Y., GÜLTEKİN M., DİZDAR Ö., YALÇIN Ş.  
TURKISH JOURNAL OF GASTROENTEROLOGY, vol.29, no.4, pp.411-418, 2018 (Journal Indexed in SCI)
- XL. **Factors associated with quitting action following smoking cessation counseling.**  
Hayran K. M. , Yuce D., Erman M., Dizdar O., Kilickap S., HUSEYİN B.  
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (Journal Indexed in SCI)
- XLI. **Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma**  
AKIN S., DİZDAR Ö., KARAKAS Y., Turker A., Kars A.  
CURRENT PROBLEMS IN CANCER, vol.42, no.3, pp.344-349, 2018 (Journal Indexed in SCI)
- XLII. **Fusobacterium and colorectal carcinogenesis**  
Güven D. C. , DİZDAR Ö.  
CARCINOGENESIS, vol.39, no.1, pp.84, 2018 (Journal Indexed in SCI)
- XLIII. **Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms**  
AKIN S., DİZDAR Ö., Hayran M.  
ANNALS OF SURGICAL ONCOLOGY, vol.24, 2017 (Journal Indexed in SCI)
- XLIV. **Tumor Sidedness and Prognosis in Colorectal Cancer: Is Microbiome the Missing Link?**  
KARAKAS Y., DİZDAR Ö.  
JAMA ONCOLOGY, vol.3, no.7, pp.1000, 2017 (Journal Indexed in SCI)
- XLV. **Evaluation of complementary and alternative medicine trials registered in clinicaltrials.gov database**  
DİZDAR Ö., BİLGİN E., AKIN S., KILIÇKAP S., HAYRAN M.  
JOURNAL OF BUON, vol.22, no.2, pp.530-534, 2017 (Journal Indexed in SCI)
- XLVI. **Increased cancer risk in patients with periodontitis**  
DİZDAR Ö., HAYRAN M., Güven D. C. , YILMAZ T. B. , TAHERİ S., AKMAN A. C. , BİLGİN E., HUSEYİN B., BERKER E.  
CURRENT MEDICAL RESEARCH AND OPINION, vol.33, no.12, pp.2195-2200, 2017 (Journal Indexed in SCI)
- XLVII. **Prognostic factors and treatment of patients with advanced synovial sarcoma: A single-center experience**  
Ateş O., Aksoy S., Yeter H., Sunar V., Kertmen N., Dizdar O., Turker A., Kars A.  
INDIAN JOURNAL OF CANCER, vol.54, no.1, pp.321-325, 2017 (Journal Indexed in SCI)
- XLVIII. **Vaccination perception and attitudes among patients with cancer receiving chemotherapy**  
AKIN Ş., DİZDAR Ö., Karakas Y., ÖZİŞİK L., Tanrıover M. D. , Kamisli S., ERMAN M., HAYRAN K. M.  
ANNALS OF ONCOLOGY, vol.27, 2016 (Journal Indexed in SCI)
- XLIX. **Response rates of taxane rechallenge in metastatic breast cancer patients previously treated with adjuvant taxanes**  
Kucukoztas N., OĞUZ A., Rahatlı S., Altundag O., Altundag K.  
JOURNAL OF BUON, vol.21, no.5, pp.1076-1081, 2016 (Journal Indexed in SCI)
- L. **Interpretation of survival data: which graphical analysis is appropriate?**  
Dizdar O., AKIN S., HAYRAN M.  
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, vol.8, no.4, pp.312, 2016 (Journal Indexed in SCI)
- LI. **Analysis of the Adjuvant Hormone Therapy Randomized Trial**  
Karakas Y., AKIN S., DİZDAR Ö., AKSOY S.  
JOURNAL OF CLINICAL ONCOLOGY, vol.34, no.17, pp.2070-2071, 2016 (Journal Indexed in SCI)
- LII. **Vaccination Attitudes Among Patients with Cancer Receiving Chemotherapy**  
AKIN S., DİZDAR Ö., ÖZİŞİK L., TANRIOVER M. D. , KAMISLI S., ERMAN M., HAYRAN M.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.3, pp.167-172, 2016 (Journal Indexed in SCI)
- LIII. **Cytoreductive Surgery for Intestinal Cancer Patients Metastatic to Ovaries Presenting as Primary Ovarian Cancer**  
Arik Z., Oz M., DİZDAR Ö., YILDIRIM M. E. , OZGU E., TERZIOĞLU S. G. , GUNGOR T.

UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.2, pp.110-115, 2016 (Journal Indexed in SCI)

- LIV. **Advances in PARP inhibitors for the treatment of breast cancer**  
DİZDAR Ö., Arslan C., ALTUNDAG K.  
EXPERT OPINION ON PHARMACOTHERAPY, vol.16, no.18, pp.2751-2758, 2015 (Journal Indexed in SCI)
- LV. **Is Dexamethasone a Better Partner for Abiraterone Than Prednisolone?**  
Dizdar O.  
ONCOLOGIST, vol.20, no.5, 2015 (Journal Indexed in SCI)
- LVI. **The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+breast cancer patients**  
BABACAN T., Balakan O., Kuzan T. Y. , Sarici F., Koca E., KERTMEN N., Petekkaya I., Altundag K.  
JOURNAL OF BUON, vol.20, no.1, pp.50-56, 2015 (Journal Indexed in SCI)
- LVII. **Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update**  
Arslan C., Dizdar O., ALTUNDAG K.  
EXPERT OPINION ON PHARMACOTHERAPY, vol.15, no.12, pp.1643-1658, 2014 (Journal Indexed in SCI)
- LVIII. **Good Outcomes of Patients with Stage IB Endometrial Cancer with Surgery Alone**  
RAHATLI S., DİZDAR Ö., KÜÇÜKÖZTAŞ N., OĞUZ A., YALÇIN S., ÖZEN Ö., Reyhan N. H. , TARHAN N. Ç. , YILDIZ F., DURSUN P., et al.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.15, no.9, pp.3891-3893, 2014 (Journal Indexed in SCI)
- LIX. **Tertiary Cancer Center Experience: Pregnancy-Associated Breast Cancer**  
Kuzas T. Y. , Koca E., BABACAN T., Turkbeyler I. H. , Sarici F., Altundag K.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.24, no.4, pp.284-285, 2014 (Journal Indexed in SCI)
- LX. **Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy**  
OZCAN M. F. , Dizdar O., DINCER N., BALCI S., Guler G., GOK B., PEKTAS G., SEKER M. M. , AKSOY S., Arslan C., et al.  
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, vol.31, no.8, pp.1709-1715, 2013 (Journal Indexed in SCI)
- LXI. **Outcomes of locally advanced breast cancer patients with  $\geq 10$  positive axillary lymph nodes**  
KOCA E., KUZAN T. Y. , Dizdar O., Babacan T., SAHIN I., ARARAT E., ALTUNDAG K.  
MEDICAL ONCOLOGY, vol.30, no.3, 2013 (Journal Indexed in SCI)
- LXII. **Breast cancer in octogenarian women: clinical characteristics and outcome**  
Kuzan T. Y. , Koca E., Dizdar O., Arslan C., Eren T., Yalcin S., Kucukoztas N., Aksoy S., Rahatli S., Dede D. S. , et al.  
JOURNAL OF BUON, vol.18, no.2, pp.328-334, 2013 (Journal Indexed in SCI)
- LXIII. **Association of breast cancer subtypes and body mass index**  
Petekkaya I., ŞAHİN U., Gezgen G., Solak M., YÜCE D., DİZDAR Ö., ARSLAN Ç., Ayyildiz V., Altundag K.  
TUMORI J, vol.99, no.2, pp.129-133, 2013 (Journal Indexed in SCI)
- LXIV. **Safety of Tamoxifen During Pregnancy: 3 Case Reports and Review of the Literature**  
Koca E., Kuzan T. Y. , BABACAN T., Turkbeyler I. H. , Sarici F., Altundag K.  
BREAST CARE, vol.8, no.6, pp.453-454, 2013 (Journal Indexed in SCI)
- LXV. **Impact of Treatment Strategies on Local Control and Survival in Uterine Carcinosarcomas in Turkey**  
Kucukoztas N., Dizdar O., Rahatli S., Dursun P., Yalcin S., Altundag O., Ozen O., Reyhan N. H. , Tarhan C., YILDIZ F., et al.  
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.14, no.5, pp.2959-2962, 2013 (Journal Indexed in SCI)
- LXVI. **Frequency of thyroid disease among breast cancer patients: a descriptive study of breast cancer patients**  
Vural O., Dizdar O., Petekkaya I., Alnak A., Babacan T., Altundag K.  
JOURNAL OF BUON, vol.18, no.1, pp.294-295, 2013 (Journal Indexed in SCI)
- LXVII. **Joint problems in breast cancer patients receiving adjuvant aromatase inhibitor**  
Kuria I. M. , Petekkaya I., Hasanov E., Babacan T., Dizdar O., Altundag K.  
JOURNAL OF BUON, vol.17, no.4, pp.798-799, 2012 (Journal Indexed in SCI)
- LXVIII. **Frequency of HCV infection in renal cell carcinoma patients**

- Budakoglu B, Aksoy S, ARSLAN Ç., Uyeturk U, Babacan N. A. , Ozcan M. F. , Yildiz R, Oven B. B. , Ozdemir N. Y. , Dizdar O., et al.  
MEDICAL ONCOLOGY, vol.29, no.3, pp.1892-1895, 2012 (Journal Indexed in SCI)
- LXIX. **Neuromyotonia forerunning the diagnosis of an eventual thymoma**  
Ozcakar L, Ozcan H. N. , Dizdar O, Karaoglanoglu N., Tan E.  
EUROPEAN JOURNAL OF NEUROLOGY, vol.19, no.9, 2012 (Journal Indexed in SCI)
- LXX. **Phase II Study of Loading-Dose Ibandronate Treatment in Patients with Breast Cancer and Bone Metastases Suffering from Moderate to Severe Pain**  
Altundag K., DİZDAR Ö., ÖZSARAN Z., ÖZKÖK S., Saip P., Eralp Y., Komurcu S., Kuzhan O., Ozguroglu M., Karahoca M.  
ONKOLOGIE, vol.35, no.5, pp.254-258, 2012 (Journal Indexed in SCI)
- LXXI. **Breast cancer subtypes and outcomes of central nervous system metastases**  
Arslan U. Y. , Oksuzoglu B., AKSOY S., Harputluoglu H., Turker I., Ozisik Y., DİZDAR Ö., Altundag K., Alkis N., Zengin N.  
BREAST, vol.20, no.6, pp.562-567, 2011 (Journal Indexed in SCI)
- LXXII. **Demographic and clinico-pathological characteristics in patients with triple-negative and non-triple-negative breast cancer**  
BULUT N., AKSOY S., DİZDAR Ö., Dede D. S. , Arslan C., DOĞAN E., Gullu I., Ozisik Y., Altundag K.  
MEDICAL ONCOLOGY, vol.28, 2011 (Journal Indexed in SCI)
- LXXIII. **Increased mean corpuscular volume of erythrocytes during capecitabine treatment: a simple surrogate marker for clinical response**  
ARSLAN Ç., AKSOY S., DİZDAR Ö., KURT M., Guler N., Ozisik Y., Gullu I., Altundag K.  
TUMORI, vol.97, no.6, pp.711-716, 2011 (Journal Indexed in SCI)
- LXXIV. **Pure mucinous carcinoma of the breast: a single center experience**  
Dogan E., Aksoy S., Dizdar O., Arslan C., Dede D. S. , Ozisik Y., Altundag K.  
JOURNAL OF BUON, vol.16, no.3, pp.565-567, 2011 (Journal Indexed in SCI)
- LXXV. **Vitamin D intake may be effective in the management of triple-negative breast cancer**  
Harputluoglu H., Dizdar O., Karaahmet F., Altundag K.  
JOURNAL OF BUON, vol.16, no.3, pp.569, 2011 (Journal Indexed in SCI)
- LXXVI. **Clinicopathologic features of patients with breast cancer under treatment of bisphosphonate at the time of diagnosis: Retrospective analysis**  
Dede D. S. , Arslan C., Aksoy S., Dizdar O., Dogan E., Alkan A., Gullu I. H. , Ozisik Y. Y. , Altundag K.  
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)
- LXXVII. **Frequency of HCV infection in renal cell carcinoma patients**  
Budakoglu B, Aksoy S, Arslan C., Uyeturk U, Babacan N. A. , Ozcan M. F. , Yildiz R, Oven B. B. , Ozdemir N., Dizdar O., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.29, no.15, 2011 (Journal Indexed in SCI)
- LXXVIII. **Nilotinib is Effective in Imatinib and Sunitinib Resistant GIST: A Case Report**  
DİZDAR Ö., YALÇIN Ş.  
HEPATO-GASTROENTEROLOGY, vol.58, no.107, pp.859-860, 2011 (Journal Indexed in SCI)
- LXXIX. **Clinical and pathological characteristics of very young breast cancer patients (<= 25 years of age)**  
Ararat E., Sahin I., Arslan C., Aksoy S., Dizdar O., Ozisik Y., Altundag K.  
JOURNAL OF BUON, vol.16, no.2, pp.372, 2011 (Journal Indexed in SCI)
- LXXX. **Percentage of family history of cancer in patients with breast cancer: Is it changing with ethnicity?**  
Dizdar O., Arslan C., Altundag K.  
JOURNAL OF BUON, vol.16, no.2, pp.373, 2011 (Journal Indexed in SCI)
- LXXXI. **Zoledronic acid and atrial fibrillation in cancer patients**  
ARSLAN Ç., AKSOY S., DİZDAR Ö., Dede D. S. , HARPUTLUOĞLU H., ALTUNDAĞ M. K.  
SUPPORTIVE CARE IN CANCER, vol.19, no.3, pp.425-430, 2011 (Journal Indexed in SCI)
- LXXXII. **Ipsilateral Breast Cancer in a Patient with Poland's Syndrome**  
Yesilkaya Y., DİZDAR Ö., Altundag K.  
AMERICAN SURGEON, vol.77, no.2, pp.234-235, 2011 (Journal Indexed in SCI)
- LXXXIII. **Malignancies after rituximab treatment: just coincidence or more?**

- Aksoy S, Arslan C, Harputluoglu H, Dizdar O, Altundag K.  
JOURNAL OF BUON, vol.16, no.1, pp.112-115, 2011 (Journal Indexed in SCI)
- LXXXIV. **Other malignancies in patients with breast cancer: a single institute experience**  
Dogan E, AKSOY S, DİZDAR Ö, ŞENER DEDE D, ARSLAN Ç, Ozisik Y, Altundag K.  
MEDICAL ONCOLOGY, vol.27, no.4, pp.1434-1435, 2010 (Journal Indexed in SCI)
- LXXXV. **Blood ABO groups and risk of breast cancer**  
ŞENER DEDE D, AKSOY S, DİZDAR Ö, Cerci P, Gullu I, Ozisik Y, Altundag K.  
MEDICAL ONCOLOGY, vol.27, no.4, pp.1433, 2010 (Journal Indexed in SCI)
- LXXXVI. **Two Important Determinants May Play a Role in the Success of the FinHer Trial**  
Isik M, DİZDAR Ö, Altundag K.  
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.20, 2010 (Journal Indexed in SCI)
- LXXXVII. **Renal safety and osteonecrosis of the jaw in cancer patients receiving intravenous bisphosphonates**  
AKSOY S, DİZDAR Ö, Altundag K.  
MEDICAL ONCOLOGY, vol.27, no.2, pp.568, 2010 (Journal Indexed in SCI)
- LXXXVIII. **Increased mean corpuscular volume of erythrocytes with capecitabine treatment in metastatic breast cancer patients: A marker of clinical benefit?**  
Aksoy S, Arslan C, Kurt M, Dizdar O, Dede D. S. , Dogan E, Gullu I. H. , Ozisik Y. Y. , Altundag M. K. , Guler N.  
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (Journal Indexed in SCI)
- LXXXIX. **Phase II study of loading-dose ibandronate treatment in patients in breast cancer and bone metastases suffering from moderate to severe pain**  
Dizdar O, Altundag M. K. , Ozkok S, Ozsaran Z, Saip P, Eralp Y, Komurcu S, Kuzhan O, Ozguroglu M., Karahoca M.  
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (Journal Indexed in SCI)
- XC. **Systemic treatment in breast-cancer patients with brain metastasis**  
Arslan C, DİZDAR Ö, Altundag K.  
EXPERT OPINION ON PHARMACOTHERAPY, vol.11, no.7, pp.1089-1100, 2010 (Journal Indexed in SCI)
- XCI. **Addition of nine weeks of trastuzumab to adjuvant chemotherapy in operable HER2-positive breast cancer patients: Retrospective analysis.**  
Ozen M, Aksoy S, Dizdar O, Dede D. S. , Dogan E, Arslan C, Gullu I. H. , Altundag M. K.  
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (Journal Indexed in SCI)
- XCII. **Docetaxel/doxorubicin/cyclophosphamide (TAC) chemotherapy for operable HER2-negative, node-positive breast cancer patients: Results from a single institution.**  
Surmell Z. G. , Aksoy S, Dizdar O, Dede D. S. , Dogan E, Arslan C, Gullu I. H. , Altundag K.  
JOURNAL OF CLINICAL ONCOLOGY, vol.28, no.15, 2010 (Journal Indexed in SCI)
- XCIII. **Skin metastasis of ovarian cancer: a rare entity**  
Arslan C, Dede D. S. , Dizdar O, Altundag K.  
JOURNAL OF BUON, vol.15, no.2, pp.398-399, 2010 (Journal Indexed in SCI)
- XCIV. **Clinical and pathological characteristics of breast cancer patients with history of tonsillectomy**  
Isik M, AKSOY S, Dede D. S. , DİZDAR Ö, Kara A, Gullu I, Ozisik Y, Altundag K.  
BREAST, vol.19, no.2, pp.152, 2010 (Journal Indexed in SCI)
- XCV. **Synchronous Ovarian Cancer in a Patient with Pleomorphic Lobular Breast Cancer: A Therapeutic Dilemma**  
Dizdar O, Arslan C, Altundag K.  
CLINICAL ONCOLOGY, vol.22, no.2, pp.153-154, 2010 (Journal Indexed in SCI)
- XCVI. **Clinical and pathological characteristics of breast cancer patients with history of cesarean delivery**  
Kalan I, Turgut D, AKSOY S, ŞENER DEDE D, DİZDAR Ö, Ozisik Y, Altundag K.  
BREAST, vol.19, no.1, pp.67-68, 2010 (Journal Indexed in SCI)
- XCVII. **Estrogen receptor immunohistochemistry cutoff value: Standardization is needed**  
ARSLAN Ç, DİZDAR Ö, Altundag K.  
HUMAN PATHOLOGY, vol.41, no.1, pp.150, 2010 (Journal Indexed in SCI)
- XCVIII. **Sonographic and Electrodiagnostic Evaluations in Patients With Aromatase Inhibitor-Related Arthralgia**



DİZDAR Ö., Oezcakar L., Malas F. U. , HARPUTLUOĞLU H., Bulut N., Aksoy S., Ozisik Y., Altundag K.  
JOURNAL OF CLINICAL ONCOLOGY, vol.27, no.30, pp.4955-4960, 2009 (Journal Indexed in SCI)

- XCIX. **Chemotherapy in Older Women with Breast Cancer**  
DİZDAR Ö., ŞENER DEDE D., Altundag K.  
NEW ENGLAND JOURNAL OF MEDICINE, vol.361, no.10, pp.1023, 2009 (Journal Indexed in SCI)
- C. **Pharmacotherapy of triple-negative breast cancer**  
ARSLAN Ç., DİZDAR Ö., Altundag K.  
EXPERT OPINION ON PHARMACOTHERAPY, vol.10, no.13, pp.2081-2093, 2009 (Journal Indexed in SCI)
- CI. **Pathological characteristics of very young (<= 30 years) breast cancer patients: a single-institution experience from Turkey**  
Aksoy S., Bulut N., Dizdar O., Tosur M., Meral A., Altundag K.  
ANNALS OF ONCOLOGY, vol.20, no.4, pp.790, 2009 (Journal Indexed in SCI)
- CII. **Reproductive and Hormonal Risk Factors for Postmenopausal Luminal, HER-2-overexpressing, and Triple-negative Breast Cancer**  
DİZDAR Ö., AKSOY S., Altundag K.  
CANCER, vol.115, no.8, pp.1802, 2009 (Journal Indexed in SCI)
- CIII. **Emerging drugs in metastatic breast cancer**  
DİZDAR Ö., Altundag K.  
EXPERT OPINION ON EMERGING DRUGS, vol.14, no.1, pp.85-98, 2009 (Journal Indexed in SCI)
- CIV. **Alterations of von Willebrand Factor and Ristocetin Cofactor Activity During Atrial Fibrillation**  
KALYONCU U., DİZDAR Ö., Duman A. E. , KARADAĞ Ö., TUFAN A., Yucel O., Tayfur O., Sen D., Ulger Z., KEPEZ A., et al.  
CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.15, no.1, pp.103-108, 2009 (Journal Indexed in SCI)
- CV. **Is initially metastatic breast carcinoma different from recurrent metastatic breast carcinoma?**  
Dizdar O., Aksoy S., Altundag K.  
ANNALS OF ONCOLOGY, vol.20, no.1, pp.189, 2009 (Journal Indexed in SCI)
- CVI. **Prognostic factors in long-term breast cancer survivors with brain metastases**  
Harputluoglu H., Kara A., DİZDAR Ö., Surmeli Z. G. , Altundag K.  
BREAST CANCER RESEARCH AND TREATMENT, vol.112, no.1, pp.215, 2008 (Journal Indexed in SCI)
- CVII. **Definition of postmenopausal status, age of the breast cancer patients and the outcome of aromatase inhibitors treatment**  
AKSOY S., DİZDAR Ö., Altundag K.  
BREAST, vol.17, no.5, pp.433-435, 2008 (Journal Indexed in SCI)
- CVIII. **Post-diagnosis statin use and breast recurrence sites in early stage breast cancer survivors**  
Harputluoglu H., DİZDAR Ö., Karaahmet F., Altundag K.  
BREAST CANCER RESEARCH AND TREATMENT, vol.110, no.3, pp.541, 2008 (Journal Indexed in SCI)
- CIX. **Weekly paclitaxel in the adjuvant treatment of breast cancer**  
AKSOY S., DİZDAR Ö., Altundag K.  
NEW ENGLAND JOURNAL OF MEDICINE, vol.359, no.3, pp.310, 2008 (Journal Indexed in SCI)
- CX. **A case report: zoledronic acid-induced anterior uveitis**  
KILIÇKAP S., Ozdamar Y., ALTUNDAĞ M. K. , DİZDAR Ö.  
MEDICAL ONCOLOGY, vol.25, no.2, pp.238-240, 2008 (Journal Indexed in SCI)
- CXI. **Aromatase inhibitor-associated arthralgia: Prevalence, clinical and serum parameters among Turkish postmenopausal breast cancer patients**  
Harputluoglu H., Dizdar O., Malas F. U. , Ozcakar L., Bulut N., Ozisik Y., Altundag K.  
JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.15, 2008 (Journal Indexed in SCI)
- CXII. **Characteristics of breast cancer patients with central nervous system metastases: A single-center experience**  
Harputluoglu H., DİZDAR Ö., AKSOY S., KILIÇKAP S., Dede D. S. , Ozisik Y., Guler N., BARIŞTA İ., Gullu I., Hayran M., et al.  
JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, vol.100, no.5, pp.521-526, 2008 (Journal Indexed in SCI)
- CXIII. **Liver dysfunction after chemotherapy in lymphoma patients infected with hepatitis C**

- DİZDAR Ö., Tapan U., AKSOY S., Harputluoglu H., KILIÇKAP S., BARIŞTA İ.  
EUROPEAN JOURNAL OF HAEMATOLOGY, vol.80, no.5, pp.381-385, 2008 (Journal Indexed in SCI)
- CXIV. **Clinicopathologic evaluation of non-Hodgkin lymphoma (NHL): A single centre experience**  
Kilickap S., Barista I., Turkmen E., Dizdar O., Aksoy S., Turker A., Gullu I., Ozisik Y., Kars A., Tekuzman G.  
JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.15, 2008 (Journal Indexed in SCI)
- CXV. **Prognostic impact of bone turnover markers in multiple myeloma**  
Dizdar O., Barista I., Kalyoncu U., Karadag O., Celik I., Kars A., Hascelik G., Cila A., Pinar A., Tekuzman G.  
JOURNAL OF CLINICAL ONCOLOGY, vol.26, no.15, 2008 (Journal Indexed in SCI)
- CXVI. **Vitamin D intake may be a predictor of response to aromatase inhibitors in postmenopausal women with hormone receptor positive breast cancer**  
DİZDAR Ö., Bulut N., Altundag K.  
BREAST CANCER RESEARCH AND TREATMENT, vol.109, no.2, pp.403, 2008 (Journal Indexed in SCI)
- CXVII. **Efficacy of chemotherapy for brain metastases from breast carcinoma: In regard to Le Scodan et al. (Int J Radia T Oncol Biol Phys 2007;69 : 839-845)**  
DİZDAR Ö., Tapan U., Altundag K.  
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol.70, no.5, pp.1615, 2008 (Journal Indexed in SCI)
- CXVIII. **Vitamin D supplementation and response to aromatase inhibitors in postmenopausal women with hormone-receptor positive breast cancer**  
DİZDAR Ö., Bulut N., Altundag K.  
BREAST, vol.17, no.2, pp.120, 2008 (Journal Indexed in SCI)
- CXIX. **Prognostic factors in breast cancer patients with brain metastases**  
Harputluoglu H., DİZDAR Ö., Altundag K.  
JOURNAL OF NEURO-ONCOLOGY, vol.87, no.2, pp.193, 2008 (Journal Indexed in SCI)
- CXX. **Erectile dysfunction in successfully treated lymphoma patients**  
AKSOY S., HARPUTLUOĞLU H., KILIÇKAP S., DİNÇER M., DİZDAR Ö., AKDOĞAN B., Ozen H., ERMAN M., ÇELİK İ.  
SUPPORTIVE CARE IN CANCER, vol.16, no.3, pp.291-297, 2008 (Journal Indexed in SCI)
- CXXI. **Familial chemosensitivity test: Can it be a predictive factor in the management of familial breast cancer?**  
DİZDAR Ö., Harputluoglu H., Altundag K.  
BREAST, vol.17, no.1, pp.5, 2008 (Journal Indexed in SCI)
- CXXII. **Role of trastuzumab in patients with brain metastases from Her2 positive breast cancer**  
Bulut N., Harputluoglu H., Dizdar O., Altundag K.  
JOURNAL OF NEURO-ONCOLOGY, vol.86, no.2, pp.241, 2008 (Journal Indexed in SCI)
- CXXIII. **Dasatinib may also inhibit c-Kit in triple negative breast cancer cell lines**  
DİZDAR Ö., ŞENER DEDE D., Bulut N., Altundag K.  
BREAST CANCER RESEARCH AND TREATMENT, vol.107, no.2, pp.303, 2008 (Journal Indexed in SCI)
- CXXIV. **Vitamin D intake and breast cancer risk in postmenopausal women**  
Dizdar O., Harputluoglu H., Altundag K.  
ARCHIVES OF INTERNAL MEDICINE, vol.167, no.22, pp.2532, 2007 (Journal Indexed in SCI)
- CXXV. **Potential targeted therapy options in the management of basal cell subtype of breast carcinoma**  
Harputluoglu H., DİZDAR Ö., Altundag K.  
HUMAN PATHOLOGY, vol.38, no.12, pp.1869, 2007 (Journal Indexed in SCI)
- CXXVI. **Efficacy of anastrozole on local recurrence in patients with favorable early breast cancer**  
DİZDAR Ö., Harputluoglu H., Altundag K.  
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, vol.69, no.5, pp.1651, 2007 (Journal Indexed in SCI)
- CXXVII. **Bone mineral density in breast cancer patients with estrogen receptor-negative tumor**  
Dede D. S. , Dizdar O., Harputluoglu H., Altundag K.  
MATURITAS, vol.58, no.3, pp.324, 2007 (Journal Indexed in SCI)
- CXXVIII. **Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer**

**patients: single center experience**

Aksoy S, Dizdar O, Harputluoglu H, Altundag K.

ANNALS OF ONCOLOGY, vol.18, no.11, pp.1904-1906, 2007 (Journal Indexed in SCI)

- CXXXIX. **Predictive factors for metastasis in patients (pts) with gastric cancer**  
Kilickap S, Dizdar O, Harputluoglu H, Aksoy S, YALÇIN S. S.  
JOURNAL OF CLINICAL ONCOLOGY, vol.25, no.18, 2007 (Journal Indexed in SCI)
- CXXX. **Appropriate utilization of hospital beds in internal medicine: evaluation in a tertiary care hospital**  
Dizdar O, Karadag O, Kalyoncu U, Kurt M., ULGER Z., SARDAN Y. C. , Unal S.  
JOURNAL OF EVALUATION IN CLINICAL PRACTICE, vol.13, no.3, pp.408-411, 2007 (Journal Indexed in SCI)
- CXXXI. **Rituximab-induced viral infections in lymphoma patients**  
Aksoy S, Harputluoglu H, Kilickap S, Dede D. S. , Dizdar O, Altundag K, Barista I.  
JOURNAL OF CLINICAL ONCOLOGY, vol.25, no.18, 2007 (Journal Indexed in SCI)
- CXXXII. **Rituximab-related viral infections in lymphoma patients**  
Aksoy S, Harputluoglu H, Kilickap S, Dede D. S. , Dizdar O, Altundag K, Barista I.  
LEUKEMIA & LYMPHOMA, vol.48, no.7, pp.1307-1312, 2007 (Journal Indexed in SCI)
- CXXXIII. **Macrophage inflammatory protein-1 alpha: A link between innate immunity and familial mediterranean fever?**  
Dizdar O, Kalyoncu U, Karadag O, Akdogan A, Kiraz S, Ertenli I, Barista I, Calguneri M.  
CYTOKINE, vol.37, no.1, pp.92-95, 2007 (Journal Indexed in SCI)
- CXXXIV. **Research for bleeding tendency in patients presenting with significant epistaxis**  
Dizdar O, Onal I. K. , Ozakin E, Karakilic E, Karadag O, Kalyoncu U, Coskun F., Buyukasik Y.  
BLOOD COAGULATION & FIBRINOLYSIS, vol.18, no.1, pp.41-43, 2007 (Journal Indexed in SCI)
- CXXXV. **Mucosa associated lymphoid tissue lymphoma of the sub mandibular gland presenting with relapse in the lacrimal gland**  
KURT M., Shorbagi A., ALTUNDAĞ M. K. , AKYÖN YILMAZ Y., DİZDAR Ö., GÜLLÜ İ. H.  
Leukemia, vol.47, pp.1982-1984, 2006 (Journal Indexed in SCI Expanded)
- CXXXVI. **Coincidence of increased pulmonary artery pressure and patent septum foramen ovate in patients with solid tumors may have a propensity to develop central nervous system metastases**  
Harputluoglu H, Dizdar O, Altundag K.  
MEDICAL HYPOTHESES, vol.67, no.4, pp.996, 2006 (Journal Indexed in SCI)
- CXXXVII. **Posterior leukoencephalopathy after combination chemotherapy in a patient with lymphoma**  
Abali H, Eren O, Dizdar O, Karadag O, Erman M, Yilmaz A, ULUÇ K, Erdem I, Turker A.  
LEUKEMIA & LYMPHOMA, vol.46, no.12, pp.1825-1828, 2005 (Journal Indexed in SCI)
- CXXXVIII. **Seropositive arthritis in chronic lymphocytic leukemia: a remark on B cell-mediated autoimmunity**  
Onal I, Ozcakar L, Dizdar O, Buyukasik Y, Dundar S.  
RHEUMATOLOGY INTERNATIONAL, vol.25, no.7, pp.569-570, 2005 (Journal Indexed in SCI)
- CXXXIX. **Orbital metastasis from adenocarcinoma of the colon**  
Dizdar O, Aksoy S, Kilickap S, Yalcin S.  
SOUTHERN MEDICAL JOURNAL, vol.98, no.8, pp.846-847, 2005 (Journal Indexed in SCI)
- CXL. **Group B streptococcal facet joint arthritis - Case report**  
Dizdar O, Alyamac E, Onal I, Uzun O.  
SPINE, vol.30, no.14, 2005 (Journal Indexed in SCI)
- CXLI. **Tumor lysis syndrome associated with fludarabine treatment in chronic lymphocytic leukemia**  
Dizdar O, Yurekli B, Purnak T, Aksu S, Haznedaroglu I.  
ANNALS OF PHARMACOTHERAPY, vol.38, pp.1319-1320, 2004 (Journal Indexed in SCI)
- CXLII. **Membranoproliferative glomerulonephritis associated with type 1 diabetes mellitus and Hashimoto's thyroiditis**  
Dizdar O, Kahraman S, Genctoy G, Ertoy D, Arici M, Altun B, Yasavul U, Turgan C.  
NEPHROLOGY DIALYSIS TRANSPLANTATION, vol.19, no.4, pp.988-989, 2004 (Journal Indexed in SCI)
- CXLIII. **Obesity: an endocrine tumor?**  
Dizdar O, Alyamac E.

## Articles Published in Other Journals

- I. **Burnout syndrome during residency in internal medicine and pediatrics in a country without working time directive**  
YAZGAN AKSOY D., DURUSU TANRIÖVER M., ÜNAL S., DİZDAR Ö., KALYONCU U., KARAKAYA KARABULUT J., KALE G.  
International Journal of Health Care Quality Assurance, 2014 (Refereed Journals of Other Institutions)
- II. **Multimodality Treatment in the Management of Anorectal Melanoma: A Case Report and Review of the Literature**  
Tapan U., DİZDAR Ö., Bulut N., ÇELİK İ.  
EURASIAN JOURNAL OF MEDICINE, vol.43, no.3, pp.189-191, 2011 (Journal Indexed in ESCI)
- III. **Current and emerging treatment options in triple-negative breast cancer**  
DİZDAR Ö., Altundag K.  
ONCOLOGY REVIEWS, vol.4, no.1, pp.5-13, 2010 (Journal Indexed in ESCI)

## Books & Book Chapters

- I. **Nutrition and Cachexia in Gastrointestinal Cancer Patients**  
HALİL M. G. , Kuyumcu M. E. , DİZDAR Ö., ÜLGER Z., YALÇIN Ş.  
in: Textbook of Gastrointestinal Oncology, Yalçın Şuayib, Philip A. Philip, Editor, Springer, pp.379-394, 2019
- II. **esophageal and gastroesophageal junction tumors**  
YALÇIN Ş., DİZDAR Ö., KILIÇKAP S., cilbir e., philip p. a.  
in: textbook of gastrointestinal oncology, Suayib Yalcin, Philip a. Philip, Editor, springer, pp.55-72, 2019

## Refereed Congress / Symposium Publications in Proceedings

- I. **Evaluation of early unplanned readmissions and predisposing factors in an oncology clinic**  
Güven D. C. , Ceylan F., Cakir I. Y. , Cesmeci E., Sayinalp B., Yesilyurt B., Guner G., Yildirim H. C. , Arik Z., Turker A., et al.  
ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31
- II. **Prognostic role of tumoral DNA damage repair protein expression in patients with resectable pancreatic cancer**  
Ceylan F., Güven D. C. , Taban H., Aktepe O., Kilickap S., Turker A., Hamaloglu E., Karakoc D., Isik A., Akyol A., et al.  
ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31
- III. **Changes in the outpatient and inpatient clinic admissions during COVID-19 pandemic: Anticipating and mitigating risks for cancer patients**  
Güven D. C. , Aktas B. Y. , Aksun M. S. , Ucgul E., Sahin T. K. , Yildirim H. C. , Guner G., Kertmen N., Dizdar O., Kilickap S., et al.  
ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31
- IV. **Relationship between sarcopenia and anthracycline related cardiotoxicity in patients with cancer**  
Bas O., Erdemir A., Onur R., Guner G., Güven D. C. , Aksu S., Kertmen N., Aksoy S., Barista I., Turker A., et al.  
ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31
- V. **Daily chemotherapy and treatment unit in the COVID-19 era: Lessons of the first 60 days**  
Aktas B. Y. , Güven D. C. , Degirmenciler R. F. , Taban H., Aktepe O. H. , Kertmen N., Kilickap S., Dizdar O., Aksoy S., Erman M., et al.  
ESMO Virtual Congress, ELECTR NETWORK, 19 September - 18 October 2020, vol.31

- VI. **outcomes of patients with resected pancreatic ductal adenocarcinoma**  
ceylan f., GÜVEN D. C. , çakır y., Hamaloglu E., Karakoc D., TÜRKER F. A. , KILIÇKAP S., YALÇIN Ş., DİZDAR Ö.  
9th international gastrointestinal cancer conference, 6 - 08 December 2019
- VII. **Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital**  
Güven D. C. , AKTEPE O. H. , Berk Z., Guner G., Taban H., AKTAŞ B. Y. , Duran Z. C. , AKIN Ş., ARIK Z., KERTMEN N., et al.  
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30
- VIII. **Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience**  
AKSOY S., DEĞİRMENCİLER R. F. , AKTAŞ B. Y. , Güven D. C. , AKTEPE O. H. , Guner G., Taban H., KERTMEN N., ARIK Z., DİZDAR Ö.  
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30
- IX. **MAY CANCER RISK BE DECREASED IN A LARGE COHORT OF CHILD AND ADULT FAMILIAL MEDITERRANEAN FEVER PATIENTS?**  
BİLGİN E., GÜVEN D. C. , Ceylan S., AYBI ÖZDEMİR Ö., KARDAŞ R. C. , FIRLATAN B., YILDIRIM T., ÖZEN S., DİZDAR Ö., HAYRAN K. M. , et al.  
Annual European Congress of Rheumatology (EULAR), Madrid, Spain, 12 - 15 June 2019, vol.78, pp.993
- X. **Effectiveness and safety of ferric carboxymaltose to treat iron deficiency anemia in cancer patients.**  
Aktas B. Y. , Kayku V. E. , Aslan A., Kertmen N., Dizdar Ö., Yalcin S., Aksoy S.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- XI. **Clinical features and prognosis of patients with liposarcoma: Single-center experience.**  
Demir M., Güven D. C. , Aktas B. Y. , Guner G., Aktepe O. H. , Taban H., Kiliçkap S., Kars A., Turker A., Yalcin S., et al.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37
- XII. **EFFECTS OF CANCER TYPES ON LOCAL AND OUT-OF-CITY ADMISSIONS FOR MEDICAL CARE**  
HAYRAN K. M. , YÜCE D., KILIÇKAP S., DİZDAR Ö., houssein b., ERMAN M., ÇELİK İ.  
ISPOR Asia Pacific 2018, Tokyo, Japan, 8 - 11 November 2018
- XIII. **TRANSCULTURAL ADAPTATION OF EORTC-QLQ-CR29 SCALE INTO TURKISH, AND ASSESSMENT OF VALIDITY ANDRELIABILITY IN TURKISH PATIENTS WITH COLORECTAL CANCER**  
HAYRAN K. M. , YÜCE D., KILIÇKAP S., houssein b., ERMAN M., DİZDAR Ö., ÇELİK İ.  
ISPOR Asia Pacific 2018, Tokyo, Japan, 8 - 11 November 2018, vol.1, pp.11
- XIV. **Kolorektal Kanserde 16S rDNA Sekanslama ile Oral Mikrobiyom Analizi**  
GÜVEN D. C. , ERGÜNAY K., BRINKMANN A., ALP A., AKDOĞAN KITTANA F. N. , AKYÖN YILMAZ Y., YILMAZ E., KARAKOÇ D., HAMALOĞLU E., YALÇIN Ş., et al.  
2. Ulusal immünoterapi ve Onkoloji Kongresi, Antalya, Turkey, 31 October - 04 November 2018
- XV. **Evaluation of cancer risk in patients with periodontal diseases.**  
GÜVEN D. C. , DİZDAR Ö., AKMAN A. C. , BERKER A. E. , YEKEDÜZ E., CEYLAN F., Baspınar B., AKBIYIK I., AKTAŞ B. Y. , YÜCE D., et al.  
2018 ASCO Annual Meeting, Chicago, United States Of America, 1 - 05 June 2018, vol.36, pp.13571
- XVI. **Kolorektal Kanserli Hastalarda Ve Sağlıklı Kontrollerde Tükürükte Fusobacterium Nucleatum, Streptococcus Gallolyticus Ve Porphyromonas Gingivalis Analizi**  
GÜVEN D. C. , DİZDAR Ö., ALP A., AKDOĞAN KITTANA F. N. , KARAKOÇ D., HAMALOĞLU E., LAÇIN Ş., KARAKAŞ Y., KILIÇKAP S., HAYRAN K. M. , et al.  
7. Türk Tıbbi Onkoloji Kongresi, Antalya, Turkey, 21 - 25 March 2018
- XVII. **Multimodality treatment in malignant peripheral nerve sheath tumors**  
KARAKAŞ Y., DİZDAR Ö., KÖSEMEHMETOĞLU K., GEDİKOĞLU M. G. , SÖYLEMEZOĞLU A. F. , BOZBULUT U. B. , demir m., KARS S. A. , TÜRKER F. A.  
International Congress on oncological sciences, 28 September - 01 October 2017

- XVIII. **Using Taylor Regression to Identify Points of Change in Local Cancer Trends**  
HAYRAN K. M. , YÜCE D., DİZDAR Ö.  
GAP 2017 CONFERENCE, 9 - 11 May 2017
- XIX. **SEVERE PERIODONTITIS IS ASSOCIATED WITH INCREASED CANCER RISK**  
DİZDAR Ö., HAYRAN K. M. , GÜVEN D. C. , Yılmaz T. B. , Taheri S., AKMAN A. C. , BİLGİN E., Hüseyin B., BERKER A. E.  
GAP 2017 Conference, Texas, United States Of America, 9 - 11 May 2017
- XX. **Smoker relatives of inpatients: A reasonable but heterogeneous target population for smoking cessation program**  
AKTAŞ B. Y. , HOUSSEİN b., YÜCE D., DİZDAR Ö., KILIÇKAP S., ERMAN M., HAYRAN K. M. , ÇELİK İ.  
7th ECTOH Conference on Tobacco or Health, Porto, Portugal, 22 - 25 March 2017
- XXI. **Evaluating Admissions of Foreign Patients to a University Hospital in Turkey**  
HAYRAN K. M. , YÜCE D., DENEK S., DİZDAR Ö.  
International Forum for Quality Cancer Care, 27 - 29 October 2016
- XXII. **Using geographical information systems to describe quality of life as a function of distance in cancer patients**  
HAYRAN K. M. , ERMAN M., KILIÇKAP S., DİZDAR Ö., YÜCE D., HÜSEYİN B., ÇELİK İ.  
ISPOR Asia Pacific Meeting 2016, 3 - 06 September 2016, vol.19, pp.892
- XXIII. **Intravenous ferric carboxymaltose treatment in cancer patients**  
ASLAN A., TAŞDEMİR V., KERTMEN N., DİZDAR Ö., AKSOY S.  
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- XXIV. **The impact of the total size of lesions in multifocal multicentric breast cancer on survival**  
Karakas Y., DİZDAR Ö., Akin S., ATEŞ Ö., ŞENDUR M. A. N. , AKSOY S., GÜLLÜ İ. H. , ÖZİŞİK Y. Y. , ALTUNDAĞ M. K.  
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- XXV. **Clinicopathologic characteristics of patients with recurrent or metastatic synovial sarcoma**  
ATEŞ Ö., AKSOY S., YETER H. H. , Akin S., KERTMEN N., DİZDAR Ö., TÜRKER F. A. , KARS S. A.  
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- XXVI. **Pleomorphic lobular carcinoma of the breast associated with impaired overall survival**  
Hacioglu M. B. , Babacan T., Diker O., Akin S., Demir M., Dizdar O., Sendur M. A. , Kilickap S., Altundag M. K.  
European Cancer Congress, Vienna, Austria, 01 January 2015, vol.51
- XXVII. **Neuroendocrine breast cancer A single center experience**  
TAŞDEMİR V., Kertmen N., CENOLİ A., KESKİN Ö., KARAKAS Y., Diker Ö., DİZDAR Ö., AKSOY S., ÖZİŞİK Y. Y. , ALTUNDAĞ M. K.  
2015 ASCO Annual Meeting, 29 May - 02 June 2015
- XXVIII. **Correlation of histopathologic response and prognostic markers with survival in locally advanced non-small cell lung cancer patients who have treated with neoadjuvant chemotherapy.**  
Kucukoztas N., Oguz A., Rahatli S., Dizdar O., Keskin G. S. Y. , Ozyilkan O., Altundag O.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXIX. **Cytoreductive surgery for intestinal cancer patients metastatic to the adnexal presenting as primary ovarian cancer.**  
Arik Z., Dizdar O., Yildirim M. E. , Ozgu E., Oz M., Terzioglu S. G. , Gungor T.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXX. **Signet ring cell carcinoma of breast: Single center experience.**  
AKIN S., DIKER O., KERTMEN N., ATEŞ Ö., DİZDAR Ö., YALÇIN Ş., Altundag K.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XXXI. **Response rates of taxane rechallenge in metastatic breast cancer patients, previously treated with**

**adjuvant taxanes.**

Oguz A., Babacan T., Dizdar O., Kucukoztas N., Rahatli S., Keskin G. S. Y. , Altundag O., Altundag K.

50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32

- XXXII. **Is there any correlation between molecular subtypes and blood groups in breast cancer?**  
Kucukoztas N., Oguz A., Babacan T., Dizdar O., Rahatli S., Sarici S. F. , Keskin G. S. Y. , Diker O., Akin S., Altundag O., et al.  
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- XXXIII. **Impact of comorbidities on recurrence rates and survival in patients with endometrial cancer.**  
Kucukoztas N., Dizdar O., Rahatli S., Tarhan C., Haberal N., Dursun P., Yalcin S., Ozen O., Yildiz F., Altundag O., et al.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XXXIV. **Outcomes of patients with endometrial cancer and aggressive histology.**  
Rahatli S., Kucukoztas N., Dizdar O., Dursun P., Yalcin S., Haberal N., Ozen O., Tarhan C., Altundag O., Yildiz F., et al.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XXXV. **Impact of treatment strategies on local control and survival in uterine carcinosarcomas.**  
Yalcin S., Dizdar O., Kucukoztas N., Rahatli S., Ozen O., Dursun P., Haberal N., Tarhan C., Yildiz F., Altundag O., et al.  
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XXXVI. **Retrospective analysis of stage IIIc uterine carcinoma patients: A single center experience.**  
Yalcin S., Rahatli S., Kucukoztas N., Ozen O., Haberal N., Tarhan C., Dursun P., Dizdar O., Yildiz F., Altundag O., et al.  
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XXXVII. **Retrospective analysis of octagenarian breast cancer patients: Multicenter retrospective study.**  
Dizdar O., Arslan C., Eren T., Yalcin S., Kucukoztas N., Aksoy S., Rahatli S., Dede D. S. , Altundag O., Zengin N., et al.  
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XXXVIII. **Outcome of breast cancer patients with stage I disease: A retrospective analysis**  
Ergun A., Kucukoztas N., Yalcin S., Rahatli S., Babacan T., Yagmurdur M. C. , Ozyilkan O., Dizdar O., Altundag O., Altundag M. K.  
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XXXIX. **Retrospective analysis of stage IC uterine cancer patients: A single center experience.**  
Kucukoztas N., Yalcin S., Rahatli S., Ozen O., Haberal N., Tarhan C., Dursun P., Dizdar O., Yildiz F., Altundag O., et al.  
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XL. **The Frequency and Determinants of Metabolic Syndrome in Patients with Operable Stage I-III Breast Cancer.**  
Aksoy S., Dizdar O., Dede D. S. , Arslan C., Dogan E., Tapan U., Ozkan C., Hesenov S., Cinel M., Yaman S., et al.  
32nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 9 - 13 December 2009, vol.69
- XLI. **Zoledronic acid and atrial fibrillation in cancer patients with bone metastases**  
Aksoy S., Dizdar O., Turgut D., Dede D. S. , Arslan C., Harputluoglu H., Altundag K.  
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27
- XLII. **Comparison of serum levels of CEA and CA 15-3 in triple-negative breast cancer at the time of metastases and serum levels at the time of first diagnosis**  
Dede D. S. , Aksoy S., Bulut N., Dizdar O., Arik Z., Gullu I., Ozisik Y., Altundag K.  
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02

June 2009, vol.27

- XLIII. **Characteristics of breast cancer patients with central nervous system metastases and factors associated with survival after development of central nervous system metastasis**  
Harputluoglu H., Dizdar O., Aksoy S., Kilickap S., Dede D. S. , Ozisik Y., Guler N., Barista I., Gullu I., Selek U., et al.  
30th Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 13 - 16 December 2007, vol.106
- XLIV. **The correlations of plasma inflammatory markers and anti-nucleosome antibodies with SLEDAI**  
Kalyoncu U., Akdogan A., Calguneri M., Karadag O., Kisacik B., Apras S., Dizdar O., Maras Y., Kiraz S., Ertenli I.  
Annual European Congress of Rheumatology, Vienna, Austria, 8 - 11 June 2005, vol.64, pp.237
- XLV. **Biochemical markers of bone turnover in the diagnosis of myeloma bone disease.**  
Dizdar O., Barista I., Kalyoncu U., Karadag O., Celik I., Kars A., Tekuzman G.  
41st Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 13 - 17 May 2005, vol.23
- XLVI. **What does determine homocysteine levels in hemodialysis patients: Nutrition or inflammation?**  
Kahraman S., Genctoy G., Yilmaz R., Dizdar O., Arici M., Altun B., Erdem Y., Yasavul U., Turgan C., Caglar S.  
36th Annual Meeting of the American-Society-of-Nephrology, SAN DIEGO, CALIFORNIA, 12 - 17 November 2003, vol.14

## Supported Projects

DİZDAR Ö., DEMİRKOL CANLI S., GÜVEN D. C. , ULUSOY S., ESENDAĞLI G., ERMAN M., KILIÇKAP S., ÖZBAY F. G. , Project Supported by Higher Education Institutions, İmmün Kontrol Noktası Blokaj Tedavisi Alması Planlanan Kanser Hastalarında Tedavi Yanıtının Genetik Ve İmmünolojik Belirleyicilerinin Araştırılması, 2019 - Continues

DİZDAR Ö., Ceylan F., AKYOL A., Project Supported by Higher Education Institutions, Pankreas kanserli hastalarda tümörde BRCA1 BRCA2 ve ATM ekspresyonunun kemoterapi yanıtı ve sağ kalım ile ilişkisinin değerlendirilmesi, 2019 - 2020

DİZDAR Ö., Güven D. C. , AKDOĞAN KITTANA F. N. , ALP A., Project Supported by Higher Education Institutions, Kolon kanseri ile tükürük mikrobiyom ilişkisi, 2017 - 2018

## Citations

Total Citations (WOS):831

h-index (WOS):15